Abstract.
We report on a chronic asymptomatic hepatitis B surface antigen (HBsAg) carrier who developed an increase in aminotransferase and HBsAg levels 1 year after lung transplantation. During treatment for cutaneous herpes simplex virus (HSV) infection with oral valaciclovir there was a marked decrease in replicating hepatitis B virus (HBV)-DNA and aminotransferase levels, which was sustained for 9 months by continuing low-dose valaciclovir. A second rise in aminotransferase levels again responded to a valaciclovir dose increase and the HBV-DNA levels declined further. Although we cannot exclude a spontaneous variation of the serologic parameters, our observation suggests that valaciclovir may represent a valuable therapeutic option in the treatment of chronic hepatitis B after lung transplantation.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Laube, I., Boehler, A., Renner, E.L. et al. Valaciclovir for Chronic Hepatitis B Virus Infection after Lung Transplantation. Infection 32, 51–53 (2004). https://doi.org/10.1007/s15010-003-3094-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s15010-003-3094-5